143 related articles for article (PubMed ID: 37156479)
1. Prostate Cancer Active Surveillance: Quality Matters.
Van Veldhuizen PJ
J Natl Compr Canc Netw; 2023 May; 21(5):529-530. PubMed ID: 37156479
[No Abstract] [Full Text] [Related]
2. Point-Counterpoint: Active Surveillance Should Still Be Preferred Management for All (or Nearly All) Men With Low-risk Prostate Cancer.
Lin DW
J Urol; 2023 Mar; 209(3):506-507. PubMed ID: 36573929
[No Abstract] [Full Text] [Related]
3. Seeking the Truth: Understanding the Impact of Missing Data on the Validity of the New Surveillance, Epidemiology and End Results Prostate with Watchful Waiting Database.
Laviana AA; Luckenbaugh AN; Wallis CJD
Eur Urol; 2020 Sep; 78(3):345-346. PubMed ID: 32059823
[No Abstract] [Full Text] [Related]
4. Population-Based Assessment of Determining Treatments for Prostate Cancer.
Chamie K; Williams SB; Hu JC
JAMA Oncol; 2015 Apr; 1(1):60-7. PubMed ID: 26182305
[TBL] [Abstract][Full Text] [Related]
5. [Active surveillance of low risk prostate cancer].
Weißbach L
Urologe A; 2015 Jun; 54(6):869-70. PubMed ID: 26081819
[No Abstract] [Full Text] [Related]
6. Active surveillance for favorable risk prostate cancer.
Carter HB
Curr Opin Urol; 2015 May; 25(3):230-1. PubMed ID: 25730328
[No Abstract] [Full Text] [Related]
7. Active Surveillance for Prostate Cancer.
Matulewicz RS; Weiner AB; Schaeffer EM
JAMA; 2017 Dec; 318(21):2152. PubMed ID: 29209723
[No Abstract] [Full Text] [Related]
8. Modern Active Surveillance in Prostate Cancer: A Narrative Review.
Pattenden TA; Samaranayke D; Morton A; Ong WL; Murphy DG; Pritchard E; Evans S; Millar J; Chalasani V; Rashid P; Winter M; Vela I; Pryor D; Mark S; Lawrentschuk N; Thangasamy IA
Clin Genitourin Cancer; 2023 Feb; 21(1):115-123. PubMed ID: 36443163
[TBL] [Abstract][Full Text] [Related]
9. Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.
Loeb S; Zhou Q; Siebert U; Rochau U; Jahn B; Mühlberger N; Carter HB; Lepor H; Braithwaite RS
Eur Urol; 2017 Dec; 72(6):899-907. PubMed ID: 28844371
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer: treatment triggers for patients on active surveillance.
Hilton WM; Parekh DJ
Nat Rev Urol; 2011 Mar; 8(3):126-7. PubMed ID: 21243020
[No Abstract] [Full Text] [Related]
11. Super active surveillance for low-risk prostate cancer | Opinion: Yes.
Reis LO; Andrade DL; Bianco FJ
Int Braz J Urol; 2019; 45(2):210-214. PubMed ID: 31021584
[No Abstract] [Full Text] [Related]
12. Further support for active surveillance in the management of low-volume, low-grade prostate cancer.
Albertsen P
Eur Urol; 2010 Dec; 58(6):836-7. PubMed ID: 20851512
[No Abstract] [Full Text] [Related]
13. Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015.
Mahal BA; Butler S; Franco I; Spratt DE; Rebbeck TR; D'Amico AV; Nguyen PL
JAMA; 2019 Feb; 321(7):704-706. PubMed ID: 30743264
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer: reducing overtreatment: active surveillance in low-risk disease.
Whitson JM; Porten SP; Carroll PR
Nat Rev Urol; 2011 Mar; 8(3):124-5. PubMed ID: 21304508
[No Abstract] [Full Text] [Related]
15. Long-term Outcomes Following Active Surveillance of Low-grade Prostate Cancer: A Population-based Study Using a Landmark Approach. Letter.
Shah N; Ioffe V
J Urol; 2023 Jun; 209(6):1108. PubMed ID: 37038888
[No Abstract] [Full Text] [Related]
16. Long-term Outcomes Following Active Surveillance of Low-grade Prostate Cancer: A Population-based Study Using a Landmark Approach. Letter.
Guidotti A; Lombardo R; De Nunzio C
J Urol; 2023 Jun; 209(6):1107-1108. PubMed ID: 37035864
[No Abstract] [Full Text] [Related]
17. Long-term Outcomes Following Active Surveillance of Low-grade Prostate Cancer: A Population-based Study Using a Landmark Approach. Letter.
Montorsi F; Stabile A; Gandaglia G; Briganti A
J Urol; 2023 Sep; 210(3):410. PubMed ID: 37449312
[No Abstract] [Full Text] [Related]
18. Active surveillance for intermediate risk prostate cancer could be risky for the patient.
Moretti K
World J Urol; 2022 Apr; 40(4):1079-1080. PubMed ID: 34212236
[No Abstract] [Full Text] [Related]
19. Active surveillance for prostate cancer: past, present and future.
Singer EA; Kaushal A; Turkbey B; Couvillon A; Pinto PA; Parnes HL
Curr Opin Oncol; 2012 May; 24(3):243-50. PubMed ID: 22450149
[TBL] [Abstract][Full Text] [Related]
20. Low risk prostate cancer: active surveillance does not increase unfavourable outcomes, study finds.
Tanne JH
BMJ; 2024 Jun; 385():q1213. PubMed ID: 38830693
[No Abstract] [Full Text] [Related]
[Next] [New Search]
